WINTON GROUP Ltd Invests $2.35 Million in Mineralys Therapeutics, Inc. $MLYS

Posted by Brenda Bartman on Jun 8th, 2026

WINTON GROUP Ltd bought a new position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) during the fourth quarter, HoldingsChannel.com reports. The fund bought 64,806 shares of the company’s stock, valued at approximately $2,352,000.

A number of other large investors have also recently made changes to their positions in MLYS. Navalign LLC bought a new stake in shares of Mineralys Therapeutics in the 4th quarter worth about $33,000. Smartleaf Asset Management LLC increased its holdings in shares of Mineralys Therapeutics by 198.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock worth $40,000 after buying an additional 676 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Mineralys Therapeutics by 14,091.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company’s stock worth $124,000 after buying an additional 3,241 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Mineralys Therapeutics by 50.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,846 shares of the company’s stock worth $140,000 after buying an additional 1,283 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Mineralys Therapeutics by 29.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 14,775 shares of the company’s stock worth $200,000 after buying an additional 3,390 shares during the last quarter. 84.46% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on MLYS shares. TD Cowen started coverage on shares of Mineralys Therapeutics in a report on Monday, April 27th. They issued a “buy” rating on the stock. Bank of America boosted their target price on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Wall Street Zen downgraded shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Tuesday, April 21st. Finally, HC Wainwright reiterated a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $49.33.

Check Out Our Latest Stock Analysis on Mineralys Therapeutics

Mineralys Therapeutics Stock Performance

Shares of NASDAQ:MLYS opened at $23.69 on Monday. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -11.56 and a beta of 0.57. Mineralys Therapeutics, Inc. has a 12 month low of $12.59 and a 12 month high of $47.65. The firm’s 50-day moving average is $27.95 and its 200 day moving average is $31.18.

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.04. As a group, equities analysts forecast that Mineralys Therapeutics, Inc. will post -2.3 EPS for the current fiscal year.

Insider Activity

In other Mineralys Therapeutics news, Director Daphne Karydas sold 3,000 shares of the business’s stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $25.00, for a total value of $75,000.00. Following the completion of the sale, the director directly owned 6,200 shares of the company’s stock, valued at $155,000. The trade was a 32.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ra Capital Management, L.P. acquired 310,700 shares of the stock in a transaction on Friday, March 27th. The stock was bought at an average cost of $23.67 per share, with a total value of $7,354,269.00. Following the completion of the transaction, the director owned 5,767,221 shares in the company, valued at $136,510,121.07. This trade represents a 5.69% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have sold 160,120 shares of company stock valued at $4,295,413. 18.94% of the stock is currently owned by company insiders.

Mineralys Therapeutics Company Profile

(Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.